Newman Hadas, Finger Paul T, Chin Kimberly J, Pavlick Anna C
The New York Eye Cancer Center, New York, New York, USA.
Eur J Ophthalmol. 2011 Nov-Dec;21(6):796-801. doi: 10.5301/EJO.2011.6477.
To evaluate the safety and effect of systemic anti-vascular endothelial growth factor bevacizumab (Avastin) in treatment of exudative retinal detachment secondary to choroidal melanoma.
Two patients were definitively treated with ophthalmic plaque radiation therapy and subsequently given 10 mg/kg intravenous bevacizumab every 2 weeks for 3 or 4 cycles.
Complete resolution of the exudative retinal detachments occurred 1.2 months and 6.5 months after completion of systemic bevacizumab and 4.7 and 10 months after plaque therapy. The first patient's visual acuity improved from counting fingers at 1 foot to 20/80 (at 40 months), while his tumor regressed from 9.2 to 3.7 mm in apical height. The second patient's initial acuity was 20/20 and final acuity was 20/80 (at 35 months), while her tumor height regressed from 12.2 to 6.3 mm. No exudative retinal detachment, intraocular or systemic tumor recurrence was noted up to 40 and 35 months, respectively. Acute side effects of intravenous bevacizumab therapy included hypertension, headaches, and amenorrhea, which shortly resolved after completion of therapy.
This pilot study suggests that systemic bevacizumab was associated with transient systemic effects as well as resolution of choroidal melanoma-related exudative retinal detachment.
评估全身应用抗血管内皮生长因子贝伐单抗（阿瓦斯汀）治疗脉络膜黑色素瘤继发渗出性视网膜脱离的安全性和疗效。
两名患者接受了眼科敷贴放射治疗，随后每2周静脉注射10mg/kg贝伐单抗，共3或4个周期。
全身应用贝伐单抗结束后1.2个月和6.5个月，以及敷贴治疗后4.7个月和10个月，渗出性视网膜脱离完全消退。第一名患者的视力从1英尺处数指提高到20/80（40个月时），而其肿瘤顶端高度从9.2mm缩小至3.7mm。第二名患者初始视力为20/20，最终视力为20/80（35个月时），其肿瘤高度从12.2mm缩小至6.3mm。分别随访至40个月和35个月时，未发现渗出性视网膜脱离、眼内或全身肿瘤复发。静脉注射贝伐单抗治疗的急性副作用包括高血压、头痛和闭经，治疗结束后很快缓解。
这项初步研究表明，全身应用贝伐单抗与短暂的全身效应以及脉络膜黑色素瘤相关的渗出性视网膜脱离消退有关。
